Interleukin-33: A novel player in osteonecrosis of the femoral head?

Joint Bone Spine

Volumn 78, Issue 6, 2011, Pages 550-554

  Saidi, Soraya ^a   Magne, David ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Alarmin; Bone remodeling; IL 33; Osteonecrosis femoral head

Indexed keywords

INTERLEUKIN 33; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; BONE NECROSIS; BONE REMODELING; BONE TURNOVER; CYTOKINE RELEASE; DRUG TARGETING; FEMUR HEAD; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; OSTEOBLAST; OSTEOCYTE; SHORT SURVEY; VASCULARIZATION;

ANIMALS; BONE AND BONES; BONE RESORPTION; BONE TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMUR HEAD NECROSIS; HUMANS; INTERLEUKINS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; OSTEOTOMY;

EID: 84855935511     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.04.013     Document Type: Short Survey

References (56)

1. Malizos K.N., Karantanas A.H., Varitimidis S.E., et al. Osteonecrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol 2007, 63:16-28.
2. Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 2006, 73:500-507.
3. Ficat R.P. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br 1985, 67:3-9.
4. Steinberg M.E., Hayken G.D., Steinberg D.R. A quantitative system for staging avascular necrosis. J Bone Joint Surg Br 1995, 77:34-41.
5. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 2002;405:14-23.
6. Gangji V., Hauzeur J.P., Matos C., et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004, 86-A:1153-1160.
7. Müller I., Vaegler M., Holzwarth C., et al. Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. Leukemia 2008, 22:2054-2061.
8. Sun Y., Feng Y., Zhang C. The effect of bone marrow mononuclear cells on vascularization and bone regeneration in steroid-induced osteonecrosis of the femoral head. Joint Bone Spine 2009, 76:685-690.
9. Lafforgue P. Mesenchymal stem cells: a new biotherapy for bone disease?. Joint Bone Spine 2010, 77:99-101.
10. Mont MA, Etienne G, Ragland PS. Outcome of nonvascularized bone grafting for osteonecrosis of the femoral head. Clin Orthop Relat Res 2003;417:84-92.
11. Cui Q, Botchwey EA. Emerging ideas: treatment of precollapse osteonecrosis using stem cells and growth factors. Clin Orthop Relat Res 2010; doi:10.1007/s11999-010-1738-1.
12. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with non traumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005, 87:2155-2159.
13. Agarwala S., Shah S., Joshi V.R. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to 8years. J Bone Joint Surg Br 2009, 91:1013-1018.
14. Johannesen J., Briody J., McQuade M., et al. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone 2009, 45:898-902.
15. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
16. Haraldsen G., Balogh J., Pollheimer J., et al. Interleukin-33 - cytokine of dual function or novel alarmin?. Trends Immunol 2009, 30:227-233.
17. Carriere V., Roussel L., Ortega N., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104:282-287.
18. Lüthi A.U., Cullen S.P., McNeela E.A., et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31:84-98.
19. Ali S., Nguyen D.Q., Falk W., et al. Caspase3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 2010, 391:1512-1516.
20. Ohno T., Oboki K., Kajiwara N., et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009, 183:7890-7897.
21. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106:9021-9026.
22. Nile C.J., Barksby E., Jitprasertwong P., et al. Expression and regulation of interleukin-33 in human monocytes. Immunology 2010, 130:172-180.
23. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin" ?. PLoS One 2008, 3:e3331.
24. Saidi S., Bouri F., Lencel P., et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 2010, 53:347-354.
25. Schulze J., Bickert T., Beil F.T., et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2010, 26:704-717.
26. Saleh H, Eeles D, Hodge JM, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 2011;152:1911-22.
27. Wood I.S., Wang B., Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009, 384:105-109.
28. Palmer G., Talabot-Ayer D., Lamacchia C., et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60:738-749.
29. Ali S., Huber M., Kollewe C., et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007, 104:18660-18665.
30. Chackerian A.A., Oldham E.R., Murphy E.E., et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179:2551-2555.
31. Hayakawa H., Hayakawa M., Kume A., et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369-26380.
32. Mun S.H., Ko N.Y., Kim H.S., et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci 2010, 67:3883-3892.
33. Joshi A.D., Oak S.R., Hartigan A.J., et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol 2010, 11:52.
34. Wei S., Kitaura H., Zhou P., et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115:282-290.
35. Lee B., Kim T.H., Jun J.B., et al. Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol 2010, 185:5926-5934.
36. Tsai CL, Liu TK. Evidence for eicosanoids within the reparative front in a vascular necrosis of human femoral head. Clin Orthop Relat Res 1992;281:305-12.
37. Rabquer B.J., Tan G.J., Shaheen P.J., et al. Synovial inflammation in patients with osteonecrosis of the femoral head. Clin Transl Sci 2009, 2:273-278.
38. Komai-Koma M., Xu D., Li Y., et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779-2786.
39. Smithgall M.D., Comeau M.R., Yoon B.R., et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
40. Moulin D., Donzé O., Talabot-Ayer D., et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007, 40:216-225.
41. Pecaric-Petkovic T., Didichenko S.A., Kaempfer S., et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009, 113:1526-1534.
42. Mayuzumi N., Matsushima H., Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009, 39:3331-3342.
43. Verri W.A., Guerrero A.T., Fukada S.Y., et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 2008, 105:2723-2728.
44. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
45. Walsh M.C., Kim N., Kadono Y., et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24:33-63.
46. Street J., Bao M., deGuzman L., et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002, 99:9656-9661.
47. Zhang G., Sheng H., He Y.X., et al. Continuous occurrence of both insufficient neovascularization and elevated vascular permeability in rabbit proximal femur during inadequate repair of steroid-associated osteonecrotic lesions. Arthritis Rheum 2009, 60:2966-2977.
48. Suzuki O., Bishop A.T., Sunagawa T., et al. VEGF-promoted surgical angiogenesis in necrotic bone. Microsurgery 2004, 24:85-91.
49. Katsube K., Bishop A.T., Simari R.D., et al. Vascular endothelial growth factor (VEGF) gene transfer enhances surgical revascularization of necrotic bone. J Orthop Res 2005, 23:469-474.
50. Choi Y.S., Choi H.J., Min J.K., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
51. Carmi Y., Voronov E., Dotan S., et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 2009, 183:4705-4714.
52. Salven P., Hattori K., Heissig B., et al. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002, 16:1471-1473.
53. Boss J.H., Misselevich I. Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 2003, 40:345-354.
54. Youm Y.S., Lee S.Y., Lee S.H. Apoptosis in the osteonecrosis of the femoral head. Clin Orthop Surg 2010, 2:250-255.
55. Weinstein R.S., Nicholas R.W., Manolagas S.C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000, 85:2907-2912.
56. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.